Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 13NETWORK 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Lymphoma 24Leukemia 18Sarcoma 17Neuroblastoma 13Central Nervous System Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Hodgkin Disease 9Breast Neoplasms 9Brain Neoplasms 9Burkitt Lymphoma 7Malignant mesenchymal tumor 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myeloid, Acute 6Leukemia, Monocytic, Acute 6Rhabdomyosarcoma 5Ovarian Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Acute 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Erythroblastic, Acute 5Kidney Neoplasms 5Testicular Neoplasms 4Teratoma 4Neutropenia 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Lung Neoplasms 4Leukemia, Biphenotypic, Acute 4Endometrial Neoplasms 4Dendritic Cell Sarcoma, Interdigitating 4

Interventions

Melphalan 5Dexamethasone 4Peripheral Blood Stem Cell Transplantation 3Filgrastim 3isatuximab 2Cyclophosphamide 2Calcium Dobesilate 2pomalidomide 1liposomal amphotericin B 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1belantamab mafodotin 1auricularum 1Watchful Waiting 1Thalidomide 1Stem Cell Transplantation 1Specimen Handling 1Moxifloxacin 1Morphine 1Magnetic Resonance Spectroscopy 1Interferon-alpha 1In Situ Hybridization, Fluorescence 1Dextromethorphan 1Cytogenetic Analysis 1Ciprofloxacin 1Caspofungin 1Bortezomib 1Biopsy 1Amoxicillin-Potassium Clavulanate Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Immunoglobulin Light-chain Amyloidosis × Filgrastim × Clear all
NCT00003353 2023-06-22

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Eastern Cooperative Oncology Group

Phase 2 Completed
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00052884 2023-06-18

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Eastern Cooperative Oncology Group

Phase 1 Terminated
8 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

NCT00064337 2018-08-09

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
104 enrolled 6 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡